Variation in NOD2 augments Th2- and Th17 responses to myelin basic protein in multiple sclerosis

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Hedegaard, Chris Juul ^a   Enevold, Christian ^a   Sellebjerg, Finn ^a   Bendtzen, Klaus ^a   Nielsen, Claus Henrik ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; MYELIN BASIC PROTEIN; TUMOR NECROSIS FACTOR ALPHA; CASPASE RECRUITMENT DOMAIN PROTEIN 15; NOD2 PROTEIN, HUMAN;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL CULTURE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MALE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; NOD2 GENE; TH17 CELL; TH2 CELL; IMMUNOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; FEMALE; GENETIC VARIATION; HUMANS; MALE; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; NOD2 SIGNALING ADAPTOR PROTEIN; TH17 CELLS; TH2 CELLS;

EID: 79956302322     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020253     Document Type: Article

References (31)

1. Medzhitov R, Janeway CA Jr, (2002) Decoding the patterns of self and nonself by the innate immune system. Science 296: 298-300.
2. Mathews RJ, Sprakes MB, McDermott MF, (2008) NOD-like receptors and inflammation. Arthritis Res Ther 10: 228.
3. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, et al. (2001) Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 276: 4812-4818.
4. Takeuchi O, Akira S, (2010) Pattern recognition receptors and inflammation. Cell 140: 805-820.
5. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, et al. (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411: 599-603.
6. Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, et al. (2001) CARD15 mutations in Blau syndrome. Nat Genet 29: 19-20.
7. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, et al. (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411: 603-606.
8. Lesage S, Zouali H, Cezard JP, Colombel JF, Belaiche J, et al. (2002) CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 70: 845-857.
9. Netea MG, Ferwerda G, de Jong DJ, Jansen T, Jacobs L, et al. (2005) Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release. J Immunol 174: 6518-6523.
10. Noguchi E, Homma Y, Kang X, Netea MG, Ma X, (2009) A Crohn's disease-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nat Immunol 10: 471-479.
11. Philpott DJ, Girardin SE, (2009) Crohn's disease-associated Nod2 mutants reduce IL10 transcription. Nat Immunol 10: 455-457.
12. Kanazawa N, Okafuji I, Kambe N, Nishikomori R, Nakata-Hizume M, et al. (2005) Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. Blood 105: 1195-1197.
13. Sawcer S, Maranian M, Hensiek A, Roxburgh R, Gray J, et al. (2003) Crohn's associated NOD2 gene variants are not involved in determining susceptibility to multiple sclerosis. J Neurol Neurosurg Psychiatry 74: 1157.
14. van Beelen AJ, Zelinkova Z, Taanman-Kueter EW, Muller FJ, Hommes DW, et al. (2007) Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity 27: 660-669.
15. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL, (2003) Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 278: 1910-1914.
16. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, et al. (2007) Phenotypic and functional features of human Th17 cells. J Exp Med 204: 1849-1861.
17. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, et al. (2005) Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6: 1123-1132.
18. Hedegaard CJ, Krakauer M, Bendtzen K, Lund H, Sellebjerg F, et al. (2008) T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology 125: 161-169.
19. Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, et al. (2007) Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 13: 1173-1175.
20. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, et al. (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201: 233-240.
21. Park H, Li Z, Yang XO, Chang SH, Nurieva R, et al. (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6: 1133-1141.
22. Hedegaard CJ, Chen N, Sellebjerg F, Sorensen PS, Leslie RG, et al. (2009) Autoantibodies to myelin basic protein (MBP) in healthy individuals and in patients with multiple sclerosis: a role in regulating cytokine responses to MBP. Immunology 128: e451-461.
23. Nielsen CH, Leslie RG, Jepsen BS, Kazatchkine MD, Kaveri SV, et al. (2001) Natural autoantibodies and complement promote the uptake of a self antigen, human thyroglobulin, by B cells and the proliferation of thyroglobulin-reactive CD4(+) T cells in healthy individuals. Eur J Immunol 31: 2660-2668.
24. Enevold C, Oturai AB, Sorensen PS, Ryder LP, Koch-Henriksen N, et al. (2009) Multiple sclerosis and polymorphisms of innate pattern recognition receptors TLR1-10, NOD1-2, DDX58, and IFIH1. J Neuroimmunol 212: 125-131.
25. Hedegaard CJ, Krakauer M, Bendtzen K, Sorensen PS, Sellebjerg F, et al. (2008) The effect of beta-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis. Clin Immunol 129: 80-89.
26. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA, (2004) Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 199: 971-979.
27. Sorensen TL, Sellebjerg F, (2001) Distinct chemokine receptor and cytokine expression profile in secondary progressive MS. Neurology 57: 1371-1376.
28. Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA, (2000) Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 105: 967-976.
29. Ochi H, Osoegawa M, Wu XM, Minohara M, Horiuchi I, et al. (2002) Increased IL-13 but not IL-5 production by CD4-positive T cells and CD8-positive T cells in multiple sclerosis during relapse phase. J Neurol Sci 201: 45-51.
30. Stromnes IM, Cerretti LM, Liggitt D, Harris RA, Goverman JM, (2008) Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat Med 14: 337-342.
31. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, et al. (2008) Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 172: 146-155.